1-20 of 20
Pekka Anttila
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Deep Immune Profiling in Multiple Myeloma at Diagnosis and Under Lenalidomide Maintenance Therapy

Raija Helena Silvennoinen, Komal Kumar Javarappa, Sini Luoma, Philipp Sergeev, Tiina J Öhman, Markku Varjosalo, Pekka Anttila, Marjaana Säily, Anu Partanen, Marja Sankelo, Caroline A. Heckman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1597.
https://doi.org/10.1182/blood-2021-149090
Published: 2021
Journal Articles

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig Cole, Cristina Gasparetto, Vania Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yanez Ruiz, Jian Y. Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij
Journal: Blood
Blood (2021) 137 (9): 1154–1165.
https://doi.org/10.1182/blood.2020008209
Published: 2021
Includes: Supplemental data
Journal Articles

Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Raija Helena Silvennoinen, MDPhD, Hareth Nahi, MD PhD, Pekka Anttila, MD, Perttu Koskenvesa, MD, Juha Lievonen, MD, Anu Marttila, MD, Ville Varmavuo, MD PhD, Anu Sikiö, MD, Marita Nurmi, MD, Marjaana Säily, MD PhD, Anu Partanen, MD PhD, Marja Sankelo, MDPhD, Sini Luoma, MD, Pentti Mäntymaa, MD PhD, Sorella Ilveskero, MD PhD, Henrik Rode Eshoj, PhD, Lene Kongsgaard Nielsen, MD PhD, Esa Jantunen, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20.
https://doi.org/10.1182/blood-2020-138447
Published: 2020
Journal Articles

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Raija Helena Silvennoinen, MDPhD, Anders Waage, MD PhD, Valdas Peceliunas, MD, Fredrik Schjesvold, MDPhD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Mervi Putkonen, MD PhD, Kristina Carlson, MD, Einar Haukaas, MD, Marja Sankelo, MDPhD, Anu Partanen, MD PhD, Damian L. Szatkowski, MDPhDMSc, Markus Hansson, MD PhD, Anu Marttila, MD, Lucia Ahlberg, MD, Per Axelsson, MD, Birgitta Lauri, MD, Maija Helena Mikkola, MD, Conny Karlsson, MD, Johanna Abelsson, MD, Erik Ahlstrand, MD PhD, Anu Sikiö, MD, Monika Klimkowska, MD PhD, Reda Matuzeviciene, MD PhD, Mona Hoysaeter Fenstad, MD PhD, Sorella Ilveskero, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-138643
Published: 2020
Journal Articles

Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma

Romika Kumari, PhD, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Juha Lievonen, MD, Raija Helena Silvennoinen, MD PhD, Pekka Anttila, MD, Caroline A Heckman, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3069.
https://doi.org/10.1182/blood-2019-128181
Published: 2019
Journal Articles

Real-World Treatment Patterns from the HUMANS Study in Multiple Myeloma in Denmark

Niels Abildgaard, MD, Anders Waage, MD PhD, Markus Hansson, MD PhD, Pekka Anttila, MD, Mate Szilcz, Yuanjun Ma, Katrine Hass Rubin, Lill-Brith von Arx, Sigurd Ørstavik, Nawal Bent-Ennakhil, Jonatan Freilich, François Gavini, Anders Green
Journal: Blood
Blood (2019) 134 (Supplement_1): 5030.
https://doi.org/10.1182/blood-2019-121953
Published: 2019
Journal Articles

Utilizing Multiple Linked Populations Registers to Estimate Incidence and Prevalence of Multiple Myeloma in Sweden and Denmark from the Real-World HUMANS Study

Markus Hansson, MD PhD, Niels Abildgaard, MD, Anders Waage, MD PhD, Pekka Anttila, MD, Anders Green, Katrine Hass Rubin, Lill-Brith von Arx, Mate Szilcz, Yuanjun Ma, Sigurd Ørstavik, Nawal Bent-Ennakhil, Jonatan Freilich, François Gavini
Journal: Blood
Blood (2019) 134 (Supplement_1): 5037.
https://doi.org/10.1182/blood-2019-121983
Published: 2019
Journal Articles

Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing Allows Identification of Physiologically Distinct Sub-Clones That Can Inform Therapeutic and Drug Development Strategies

Despina Bazou, BSc, MSc, PhD, Muntasir M Majumder, MSc, BPharm, Ciara Tierney, BSc, Sinead O'Rourke, BSc, Pekka Anttila, MD, Raija Helena Silvennoinen, MD PhD, Caroline A Heckman, PhD, Paul Dowling, BSc, PhD, Peter O'Gorman, MD PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 1901.
https://doi.org/10.1182/blood-2018-99-115910
Published: 2018
Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Katja Weisel, MD, Meletios A Dimopoulos, MD, Philippe Moreau, Munci Yagci, Alessandra Larocca, MD, Abraham S. Kanate, MD, Filiz Vural, Nicola Cascavilla, MD, Supratik Basu, MBBS, MD FRCP, FRCPath, Peter Johnson, Peter D. Byeff, MD, Marek Hus, Paula Rodriguez Otero, MD, Kosei Matsue, MD PhD, Ercan Muelduer, Pekka Anttila, MD, Patrick Hayden, Maria-Theresa Krauth, MD, Dina Ben-Yehuda, MD, Larisa P. Mendeleeva, MD PhD Prof, Shien Guo, Lea Purnomo, Xin Yu, Lara Grote, Tsvetan Biyukov, MD, Mohamed Zaki, MD PhD, Paul Richardson
Journal: Blood
Blood (2018) 132 (Supplement 1): 1960.
https://doi.org/10.1182/blood-2018-99-112155
Published: 2018
Journal Articles

A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

Raija Helena Silvennoinen, MDPhD, Dimitrios Tsallos, BSc(Hons),MSc, Hareth Nahi, MD PhD, Pekka Anttila, MD, Perttu Koskenvesa, MD, Juha Lievonen, MD, Anu Räsänen, MD, Ville Varmavuo, MD PhD, Anu Sikiö, MD, Marita Nurmi, MD, Marjaana Säily, MD PhD, Anu Partanen, MD, Marja Sankelo, MDPhD, Sini Luoma, MD, Sorella Ilveskero, MD PhD, Tarja-Terttu Pelliniemi, MD PhD, Esa Jantunen, MD PhD, Muntasir M Majumder, MSc, BPharm, Samuli Eldfors, PhD, Maija Leppä, MSc(Tech), Caroline A Heckman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1975.
https://doi.org/10.1182/blood-2018-99-114593
Published: 2018
Journal Articles

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Meletios A Dimopoulos, MD, Sara Bringhen, MD, Pekka Anttila, MD, Marcelo Capra, MD PhD, Michele Cavo, MD, Craig E. Cole, MD, Cristina J Gasparetto, MD, Vania T. M. Hungria, MD PhD, Matthew Jenner, Vladimir Vorobyev, MD PhD, Eduardo Yanez Ruiz, Jianyun Yin, Anthony Hamlett, Ravi Vij, MBBS
Journal: Blood
Blood (2018) 132 (Supplement 1): 155.
https://doi.org/10.1182/blood-2018-155
Published: 2018
Journal Articles

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Muntasir M Majumder, MSc, BPharm, David Tamborero, PhD, Pekka Anttila, Raija Helena Silvennoinen, MD, Samuli Eldfors, MSc, Juha Lievonen, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Esa Jantunen, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4412.
https://doi.org/10.1182/blood.V130.Suppl_1.4412.4412
Published: 2017
Journal Articles

RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow

Raija Silvennoinen, MD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Tuija Lundan, PhD, Jouni Heiskanen, MD, Timo Siitonen, MD PhD, Sakari Kakko, MD PhD, Mervi Putkonen, MDPhD, Hanna Ollikainen, MD, Venla Terävä, MD, Anu Partanen, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MD PhD, Juha Lievonen, MD, Tuomas Selander, MSc, Imre Västrik, Dr, PhD, Tarja-Terttu Pelliniemi, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MD PhD, Esa Jantunen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 676.
https://doi.org/10.1182/blood.V128.22.676.676
Published: 2016
Journal Articles

DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors

Muntasir M Majumder, MSc, MPharm, David Tamborero, PhD, Pekka Anttila, MD, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Ashwini Kumar, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Esa Jantunen, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2016) 128 (22): 198.
https://doi.org/10.1182/blood.V128.22.198.198
Published: 2016
Journal Articles

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Clinical Trials & Observations
Meletios A. Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Francesco Di Raimondo, Katja C. Weisel, Albert Oriol, Markus Hansson, Angelo Vacca, María Jesús Blanchard, Hartmut Goldschmidt, Chantal Doyen, Martin Kaiser, Mario Petrini, Pekka Anttila, Anna Maria Cafro, Reinier Raymakers, Jesus San-Miguel, Felipe de Arriba, Stefan Knop, Christoph Röllig, Enrique M. Ocio, Gareth Morgan, Neil Miller, Mathew Simcock, Teresa Peluso, Jennifer Herring, Lars Sternas, Mohamed H. Zaki, Philippe Moreau
Journal: Blood
Blood (2016) 128 (4): 497–503.
https://doi.org/10.1182/blood-2016-02-700872
Published: 2016
Journal Articles

Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease

Muntasir Mamun Majumder, MSc,MPharm, Raija Silvennoinen, MD, Pekka Anttila, MD, David Tamborero, PhD, Samuli Eldfors, MSc, Juha Lievonen, MD, Riikka J Karjalainen, Heikki Kuusanmäki, MSc, Alun Parsons, Minna Suvela, Kimmo Porkka, MD PhD, Caroline Heckman
Journal: Blood
Blood (2015) 126 (23): 3006.
https://doi.org/10.1182/blood.V126.23.3006.3006
Published: 2015
Journal Articles

A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

Raija Silvennoinen, MD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Tuija Lundan, PhD, Jouni Heiskanen, MD, Timo Siitonen, MD PhD, Sakari Kakko, MD PhD, Mervi Putkonen, MDPhD, Hanna Ollikainen, MD, Venla Terävä, MD, Anu Partanen, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MD PhD, Tuomas Selander, MSc, Taru Kuittinen, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MDPhD, Esa Jantunen, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1977.
https://doi.org/10.1182/blood.V126.23.1977.1977
Published: 2015
Journal Articles

Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response

David Tamborero, PhD, Muntasir Mamun Majumder, MSc,BPharm, Raija Silvennoinen, MD, Samuli Eldfors, MSc, Pekka Anttila, MD, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, BSc, Marjanna Säily, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2014) 124 (21): 3351.
https://doi.org/10.1182/blood.V124.21.3351.3351
Published: 2014
Journal Articles

A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma

Raija Silvennoinen, MD, Tuija Lundan, PhD, Pekka Anttila, MD, Jouni Heiskanen, MD, Marjaana Säily, MDPhD, Timo Siitonen, MDPhD, Sakari Kakko, MDPhD, Hanna Ollikainen, MD, Seppo Vanhatalo, MD, Mervi Putkonen, MDPhD, Venla Terävä, MD, Anu Kutila, MD, Mari Partio, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MDPhD, Taru Kuittinen, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MD PhD, Esa Jantunen, MDPhD
Journal: Blood
Blood (2014) 124 (21): 847.
https://doi.org/10.1182/blood.V124.21.847.847
Published: 2014
Journal Articles

Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma

Raija Silvennoinen, MD, Muntasir Mamun Majumder, MSc,BPharm, David Tamborero, PhD, Pekka Anttila, MD, Samuli Eldfors, MSc, Riikka Karjalainen, MSc, Heikki Kuusanmäki, MSc, Juha Lievonen, MD, Alun Parsons, MSc, Minna Suvela, Marjaana Säily, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2014) 124 (21): 646.
https://doi.org/10.1182/blood.V124.21.646.646
Published: 2014